Skip to content

Vorinostat

Published: July 26, 2026Updated: July 26, 2026

Vorinostat is an antineoplastic medication classified as a histone deacetylase (HDAC) inhibitor used primarily for the treatment of cutaneous T-cell lymphoma (CTCL) in patients whose disease has progressed, persisted, or recurred following at least one prior systemic therapy. By inhibiting HDAC enzymes, vorinostat promotes acetylation of histones and other proteins, leading to altered gene expression, cell cycle arrest, and apoptosis in cancer cells.

Quick summary

Vorinostat is a histone deacetylase inhibitor used to treat cutaneous T-cell lymphoma in patients who have failed prior systemic therapy.

Medically reviewed by WellAlly Editorial TeamLast reviewed July 26, 2026Editorial policy

Key facts at a glance

ATC
L01XH01
RxNorm
194337
Generic
Vorinostat
Class
atc-l01
Brands
Zolinza
Availability
rx
Lactation
unknown
Routes
oral
Forms
capsule
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Treatment of cutaneous T-cell lymphoma (CTCL) in patients with progressive, persistent, or recurrent disease on or following at least one systemic therapy.

Inhibits histone deacetylases (HDAC1, HDAC2, HDAC3 from Class I and HDAC6 from Class II) at nanomolar concentrations (IC50 <86 nM), preventing removal of acetyl groups from lysine residues on histone proteins, thereby altering gene expression and inducing cell differentiation, cell cycle arrest, and apoptosis in malignant cells.

Common adverse effects include fatigue, nausea, diarrhea, anorexia, and hematologic toxicities including thrombocytopenia and anemia. Regular monitoring of blood counts and electrolytes is recommended. Use with caution in patients with pre-existing hepatic or renal impairment. May cause fetal harm if administered during pregnancy.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed July 26, 2026. · Read our editorial policy